Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 3/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20436438 | 0.87 | TSHR (0.37) | CCR1GABRA1GABRG2GABRB3IRAK4 | |
| SCHEMBL20738454 | 0.87 | PARP1 (0.35) | TRPV3TRPA1CXCR4 | |
| SCHEMBL4047127 | 0.84 | GABRA1 (0.42) | CCR1GABRA1GABRG2GABRB3TRPV3 | |
| SCHEMBL17827972 | 0.82 | HTT (0.42) | CCR1TRPA1 | |
| SCHEMBL20738703 | 0.82 | HTT (0.42) | CCR1TRPA1 | |
| SCHEMBL19085083 | 0.82 | CCR1 (0.39) | CCR1GABRA1GABRG2GABRB3TRPV3 | |
| SCHEMBL20416692 | 0.82 | CCR1 (0.39) | CCR1GABRA1GABRG2GABRB3TRPV3 | |
| SCHEMBL19077721 | 0.82 | CCR1 (0.33) | CCR1GABRA1GABRG2GABRB3TRPV3 | |
| SCHEMBL20738460 | 0.81 | CCR1 (0.42) | CCR1GABRA1GABRG2GABRB3TRPV3 | |
| SCHEMBL29337105 | 0.81 | IRAK4 (0.44) | CCR1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018136700-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. (US) | 2018-07-26 | — | — | WO | disclosed |